|
|
Blood, Vol. 108, Issue 7, 2384-2391, October 1, 2006
CD32B, the human inhibitory Fc- receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma
Blood Rankin et al.
108: 2384
Supplemental materials for: Rankin et al
Files in this Data Supplement:
- Figure S1. Aglycosylated 2B6 antibody binding to CD32A-R131 or CD32B expressing CHO cells (JPG, 60.2 KB)
-
Stably transfected CHO cells expressing CD32A-R131 (left panels) or CD32B (right panels) were incubated in PBS-1%BSA-SA with 3ug/ml of aglycosylated, chimeric 2B6 (ch2B6-N297Q), aglycosylated, humanized 2B6 (hu2B6-3.5-N297Q), aglycosylated IV.3 (IV.3-N297Q) or FLI8.26 (bold lines). Isotype control antibody staining is represented by the dotted lines. Primary antibodies were washed twice in PBS-1%BSA-SA and bound antibody was detected using PE-labeled goat F(ab′)2 anti-mouse (H+L) IgG or PE-labeled goat F(ab′)2anti-human Fc-specific secondary antibody. Samples were then washed with an excess of PBS and then analyzed by flow cytometry using a FACS Calibur.
|
|
